Jeffrey M. Jacobson, MD; Barbara J. Turner, MD; Elias Abrutyn, MD
Potential Financial Conflicts of Interest: Grants received: B. Turner (Pfizer).
Requests for Single Reprints: Jeffrey M. Jacobson, MD, Division of Infectious Diseases and HIV Medicine, Drexel University College of Medicine, 245 North 15th Street, Mail Stop 461, Philadelphia, PA 19102; e-mail, email@example.com.
Current Author Addresses: Dr. Jacobson: Drexel University College of Medicine, 245 North 15th Street, Mail Stop 461, Philadelphia, PA 19102.
Dr. Turner: Division of General Internal Medicine, University of Pennsylvania School of Medicine, 1123 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104-6021.
Jacobson J., Turner B., Abrutyn E.; Trials That Matter: CD4+ T-Lymphocyte Count–Guided Interruption of Antiretroviral Therapy in HIV-Infected Patients. Ann Intern Med. 2007;146:682-683. doi: 10.7326/0003-4819-146-9-200705010-00014
Download citation file:
Published: Ann Intern Med. 2007;146(9):682-683.
Editor's Note:We are deeply sorry to report that Dr. Abrutyn died unexpectedly while preparing this editorial for publication. He was an associate editor of Annals for 29 years, which is just one of many accomplishments of a splendid life in medicine. An appreciation of his career appears elsewhere in this issue.
Advances in antiretroviral chemotherapy have been remarkably successful in suppressing HIV replication, preventing or reversing much of the immunologic damage from HIV infection, reducing the incidence of clinical events and hospitalizations, and prolonging life (1). However, treatment is merely suppressive, not curative (2), and antiretroviral therapy is associated with clinical toxicity, emergence of drug resistance, substantial cost, and burdensome pill-taking. As a result, the concept of structured interruptions to treatment is attractive. Proponents of structured treatment interruption have had several theoretical goals, including providing pulse exposures of viral antigens as an autoimmunization strategy to boost anti-HIV immune responses (3–5); repopulating with drug-sensitive “wild-type” virus in persons with multidrug-resistant HIV (6–9); and reducing drug exposure and its adverse clinical, social, and economic consequences (10–12).
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Infectious Disease, HIV.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only